Valdés DKC, Hernández-Negrín H, López SA, Valdés LL, Vila TAA, Tejeda RMC

Language: Spanish
References: 10
Page: 1-5
PDF size: 249.07 Kb.

ABSTRACT

Research in the last decade has shown that the risk of developing lymphoma in patients with rheumatoid arthritis is twice the risk of the general population. However, there is not data on the magnitude of this problem in Cuba.We present the cases of three patients with a diagnosis of seropositive rheumatoid arthritis treated with methotrexate who during their evolution developed non- Hodgkin's lymphoma.The patients received first-line chemotherapy and they achieved total remission with three-year survival so far.The diagnosis of lymphoproliferative diseases in patients with rheumatoid arthritis is a challenge; therefore, a high index of suspicion is necessary that, in the absence of reliable markers of lymphomagenesis, allows the timely management of these patients.

REFERENCES

1. Yadlapati S, Efthimiou P. Autoimmune/Inflammatory arthritis associated lymphomas: who is at risk? Biomed Res Inter. 2016;2016: 8631061.

2. Klein A, Polliack A, Gafter-Gvili A. Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome. Hematol Oncol. 2018:1-7.

3. Hellgren K, Baecklund E, Backlin C, Sundstrom C, Smedby KE, Askling J. Rheumatoid arthritis and risk of malignant lymphoma: Is the risk still increased? Mod Rheumatol. 2017;69(4):700-8.

4. Turesson C. Comorbidity in rheumatoid arthritis. Swiss Med Wkly. 2016;146(1314).

5. Hwajeong L. The risk of malignancy in korean patients with rheumatoid arthritis. Yonsei Med J. 2019;60(2):223-9.

6. Serra Valdés MA, Landrian DavisI A, Ramos RiveroI AI, Reyes Prolong Y, Aranguren Barreto O, Herrera Calderón Y. Lupus eritematoso sistémico y linfoma no Hodgkin de células T. Presentación de caso y revisión de la literatura. Rev Cub Reumatol. 2016;18(1):1-9.

7. Luna Conde CM, Figueredo Peguero YE, Wilford De León M, Reyes Llerena AG, Hernández Mártínez A, Alfonso Sabatier C. Linfomas asociados a enfermedades reumatológicas. Invest Medicoquir. 2014;6(1):98-106.

8. Saburi M, Ogata M, Yoshida N, Nashimoto Y, Moroga Y, Takano K, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorder, hodgkin type, following epstein-barr viral hepatitis in a patient with rheumatoid arthritis. Internal Medicine. 2018;57:1145-9.

9. Katsuyama T, Sada KE, Yan M, Seggar S, Hiramatsu S. Prognostic factors of methotrexateassociated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents Mod Rheumatol. 2017;17(5):101-9.

10. Mejía Freire S, Molina Calderón A, Duque Proaño G, Arias Maldonado F. Características clínicas, demográficas e histopatológicas de pacientes con diagnóstico de linfoma no Hodgkin. Rev Med HJCA. 2015;3(7).